Management of Childhood Pancytopenia

May 9, 2018 updated by: Asmaa Otify, Assiut University

Management of Childhood Pancytopenia in Heamatology Unit in Assiut University Hospital

Pancytopenia is an important hematologic Problem.it is a decrease in all three cellular elements of peripheral blood leading to aneamia, leucopenia and thrombocytopenia.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Pancytopenia usually presents with symptoms of bone marrow failure such as pallor, dysnea, brusing and increased tendency to infections.

The incidence of various disorders causing pancytopenia varies according to Geographical distribution and genetic mutations. It can result from :

  • Failure of production of hematopoietic progenitors in bone marrow as in aplastic aneamia.
  • Bone marrow infiltration by malignant cells as in acute leukemia.
  • Antibodies mediated bone marrow suppression as in systemic lupus.
  • Ineffective hematopoiesis and dysplasia as in nutrition deficiency.
  • Peripheral sequestration of blood cells in over active reticuloendothelial system as in hypersplenism.

Pancytopenia is not a disease entity but a triad of findings that may result from primary or secondary bone marrow involvement.

Bone marrow aspiration and biopsy evaluation along with clinical correlation are important to evaluate the causes of pancytopenia and plan further investigations and treatment.

Pancytopenia can result from damage to bone marrow evidanced by low reticulocyte count, or increased destruction of the peripheral blood with increased reticulocyte count.

Bone marrow examination is a simple and safe invasive procedure for evaluating the causes of pancytopenia.

The hypoplastic marrow which occurs in 2% of pediatrics acute lymphoblastic leukemia may be misdiagnosed as aplastic aneamia.

Studies done have shown leukemia to be the second most common cause of pancytopenia in pediatrics, marginally behind aplastic aneamia.

Study Type

Observational

Enrollment (Anticipated)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 weeks to 18 years (Child, Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Childrens and adolescents from age one month up to 18 years old suffering from pancytopenia.

Description

Inclusion Criteria:

  • All childrens and adolescents suffering from pancytopenia attending heamatology unit of pediatric department Assiut University Hospital will be included.

Exclusion Criteria:

  • childrens and adolescents suffering from pancytopenia due to malignancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
One group of children below 18 years old
Diagnostic test: Complete blood picture
Iaboratory investigation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Availability
Time Frame: One year
Bone marrow examination for all cases [evaluate the causes of pancytopenia and plan further investigations and treatment.]
One year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modification
Time Frame: One year
Guidelines for management of pancytopenia modified or not? [Strategy of blood elements transfusion in treatment]
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2018

Primary Completion (Anticipated)

June 1, 2019

Study Completion (Anticipated)

December 1, 2019

Study Registration Dates

First Submitted

April 17, 2018

First Submitted That Met QC Criteria

May 9, 2018

First Posted (Actual)

May 11, 2018

Study Record Updates

Last Update Posted (Actual)

May 11, 2018

Last Update Submitted That Met QC Criteria

May 9, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MCP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancytopenia

Clinical Trials on Complete blood picture

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe